Drug-induced blood dyscrasias with onset of respiratory symptoms

A patient, diagnosed with ulcerative colitis and rheumatoid arthritis and treated with mesalazine and hydroxychloroquine, presented with symptoms of catarrh similar to those of COVID-19. The pharmacotherapeutic monitoring service (PMS) provided to the patient allowed us to associate these symptoms with a side effect of the drug taken by the patient, i.e., blood dyscrasias. The intervention, carried out to inform the doctor while the patient was symptomatic, allowed the HCP to modify the treatment by reducing the doses of the drugs used until the condition was under control.